Educating Through Medical Animations, Cases and More | Free CME Activities

Page 3 of 8

Results 151 - 225 of 567

Emerging Nonfactor Approaches for Patients with Hemophilia

Identification of Relapsed ALL

ILD Patient Case Library: IPF, PF-ILD, SSc-ILD, and Post COVID-19

PAH: Risk Reduction Strategies Using Single and Combination Therapies

Ensuring Effective Care Transitions in Beta Thalassemia

Improved Patient Outcomes in PAH

Principles of Management of Chronic GVHD

Diagnosing and Assessing Chronic Graft-versus-Host Disease

IPF Management and Antifibrotic Therapy

How to Develop an Effective Risk Reduction Strategy in Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension (PAH) - Therapy Options Explained

Updates in Duchenne Muscular Dystrophy: A Focus on Emerging Gene Therapy

EXPLORE Learning Experience: COVID-19 and Monoclonal Antibodies

EXPLORE Learning Experience: Understanding and Managing NTM-Lung Disease

Cardiac Amyloidosis: Is It A Zebra or A Horse? Webinar Summary Module

Cardiac Amyloidosis Webinar #4: Treatment of Cardiac Amyloidosis

Cardiac Amyloidosis Webinar #3: Establishing the Correct Diagnosis

Cardiac Amyloidosis Webinar #2: Cardiac Imaging Pearls

Cardiac Amyloidosis Webinar #1: Who Should I be Testing?

Updates in Diabetes Care for Primary Care Providers

Osteoporosis Updates: Primary Care’s Critical Role

Primary Care and Dyslipidemia: What Should You Do?

Staying Current in Obesity Management: Key Updates for Primary Care

Thyroid Assessment: Updates for Primary Care

A New Paradigm in Treating ILD

A Collaborative Approach to IPF Management

Practical Solutions to SSc-ILD Treatment

Post COVID-19 and Patients With and Without Pre-existing ILD

Exploring CGM: Achieving Treatment Goals Together

Reversing DOACS: Providing Answers to What, Where and How

How to Choose the Right Therapy for Your Patients with IPF

PAH: Aligning Treatment Strategy to Risk Level

PAH: Identifying Side Effects and Optimizing Therapy to Improve Patient Outcomes

LGMD: Mutation-specific Nomenclature

LGMD Symptomatology

LGMD Mutations and Disease Types

Tests and Outcomes - DMD

Genes, Exons, and the Pathophysiology of DMD

The Natural History of DMD

Reversing DOACS: Recording from Live Session held on July 18, 2021

Conquer the Clot: Addressing VTE in Your Patients with Cancer

Patient Develops de novo Features of ILD After a COVID Infection

SSc-ILD Individualized Treatment

Overlapping Symptoms and Risk Factors for COVID and IPF

Multidisciplinary Management of IPF

Fundamentals of Diagnosis: SSc-ILD

Fundamentals of Diagnosis: PF-ILD

Updates in SMA: Cure SMA Conference Coverage (CME/CE)

9076-0001-263x149

Healthcare Disparities in African Americans With Myeloma

Beyond The Basics Of PAH

Pediatric GHD: Working Together To Ensure Success

New and Emerging Options for the Management of MS

Perioperative Nutrition and Wound Healing

Special Considerations for Nutrition for the Elderly

Diabetes & Nutrition

Comorbidities and Selection of DMTs

Itching for Relief: Atopic Dermatitis Management Considerations for PAs and NPs

IPF Management in Practice: A Truly Interactive Experience

Conference Coverage on DMD and LGMD: Latest Developments

Management of Breakthrough Disease Activity in MS

Key Considerations: Advances in Gene Therapy for Hemophilia

Highlights From the EAHAD 2021 Virtual Congress

Updated Follow-up of the Alta Study, Giroctocogene Fitelparvovec (SB-525)

First Data From the Phase 3 HOPE-B Gene Therapy Trial

The World Federation of Hemophilia Gene Therapy Registry

Etranacogene Dezaparvovec, an Enhanced Vector for Gene Transfer in Adults (Pipe)

AMT-060 Gene Therapy in Adults With Severe or Moderate-Severe Hemophilia B (Leebeek)

AMT-060 Gene Therapy in Adults With Severe or Moderate-Severe Hemophilia B (Miesbach)

First-in-Human Gene Therapy Study of AAVhu37 Capsid Vector Technology

Characterisation of Adeno-Associated Virus Vector Persistence

Follow-up on a Novel Adeno-Associated Virus (AAV) Gene Therapy (FLT180a)

Etranacogene Dezaparvovec, an Enhanced Vector for Gene Transfer in Adults (Drygalski)

Efficacy and Safety of Etranacogene Dezaparvovec in Adults

COVID-19 Associated ARDS

COVID-19 and Comorbid ILD

Page 3 of 8